V4262
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse
clone FLT-11, ascites fluid
Synonym(s):
Anti-Flt1 Receptor, Anti-VEGF R-1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
FLT-11, monoclonal
mol wt
antigen 160-200 kDa
contains
15 mM sodium azide
species reactivity
human
technique(s)
immunocytochemistry: suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
indirect ELISA: suitable
western blot: 1:500 using VEGF Receptor-1 (Flt-1)/Fc Chimera human recombinant
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... FLT1(2321)
General description
Vascular Endothelial Growth Factor Receptor-2 (VEGF R2) is a 160-200kD protein that belongs to protein kinase superfamily and is expressed mainly on the surface of various endothelial cells. It plays a pivotal role in the regulation of angiogenesis, cell migration, cell survival and cancer cell invasion. ASV derived from VEGF receptor type 1 serve as a potential therapeutics for rheumatoid arthritis. Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1antibody can be used in western blotting (diluted 1:500) using VEGF Receptor-1 (Flt-1)/Fc Chimera human recombinant. It can also be used in indirect ELISA. Mouse anti-Vascular Endothelial Growth Factor Receptor-1antibody reacts specifically with an epitope within amino acids 1-251 of the extracellular domain of human VEGF Receptor-1 but not with VEGF Receptor-2 (KDR). The product has shown cross reactivity with the mouse Flt1 receptor.
Vascular endothelial growth factor (VEGF) is also called vasculotropin (VAS) and vascular permeability factor (VPF). It is a homodimeric heparin-binding glycoprotein.
Specificity
Mouse monoclonal clone FLT-11 anti-VEGF R-1 antibody reacts specifically with the extracellular domain of human VEGF Receptor-1. The epitope recognized by the antibody resides within amino acid residues 1-251 of the VEGF Receptor-1 molecule. The product does not recognize VEGF Receptor-2 (KDR).
Immunogen
recombinant human VEGF-1 receptor.
Application
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody can be used in several immunochemical assays like immunohistochemistry, immunocytochemistry and immunoprecipitation for the localization of VEGF-R1.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Meiying Zhang et al.
Journal of ovarian research, 7, 19-19 (2014-02-11)
Tumor-associated macrophages (TAMs) are classified into two major phenotypes, M1 and M2. M1 TAMs suppress cancer progression, while M2 TAMs promote it. However, little is known regarding the role of TAMs in the development of ovarian cancer. Here, we investigated
A Rajakumar et al.
Placenta, 26(7), 563-573 (2005-07-05)
The soluble VEGF receptor, sFlt-1 (otherwise referred to as sVEGFR-1), has been implicated in the pathogenesis of preeclampsia. The preeclamptic placenta has been previously demonstrated to produce high levels of the soluble VEGF receptor. Here we tested the hypothesis that
Y K Y Lai et al.
Gene therapy, 9(12), 804-813 (2002-06-01)
Neovascularisation (NV) within the eye often results in visual loss. Vascular endothelial growth factor (VEGF) has been implicated in the development of ocular NV. Previous studies have shown that VEGF antagonists successfully suppressed retinal and choroidal NV in animal models.
Paul-Eduard Neagoe et al.
The Journal of biological chemistry, 280(11), 9904-9912 (2005-01-08)
We previously reported that vascular endothelial growth factor (VEGF)-A(165) inflammatory effect is mediated by acute platelet-activating factor synthesis from endothelial cells upon the activation of VEGF receptor-2 (VEGFR-2) and its coreceptor, neuropilin-1 (NRP-1). In addition, VEGF-A(165) promotes the release of
Gandham Mahendra et al.
Cancer gene therapy, 12(1), 26-34 (2004-09-11)
Antiangiogenic gene transfer has the potential to be more efficacious than protein-based therapies or pharmacotherapies for the control of solid tumor growth, invasion and metastasis. For a sustained antiangiogenic effect, a vector capable of long-term expression without vector-associated immunity or
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service